Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Enphase Energy Inc (ENPH) vs Pfizer Inc (PFE) Price & Performance

Enphase Energy IncTrade
Pfizer IncTrade

Price performance (Past 24H)

Key statistics

Enphase Energy Inc vs Pfizer Inc — how do they compare? Enphase Energy Inc trades at $42.32 (market cap $5.41B), while Pfizer Inc trades at $26.59 (market cap $154.18B). The key difference: Pfizer Inc is far larger — about 28.5× Enphase Energy Inc's market cap, and Pfizer Inc pays a 6.36% dividend while Enphase Energy Inc pays none. Which is the better fit depends on your goals.

ENPHPFE
Market Cap
$5.41B$154.18B
Sector
TechnologyHealth
52-Week High
$72.33$28.56
52-Week Low
$26.12$23.60
Enterprise Value
$5.05B$205.67B
Volume
29,869,932
Dividend Yield
6.36%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Enphase Energy Inc

Enphase Energy (ENPH) trades at $41.87, up 5.55% with bullish technical signals and mixed quarterly earnings. The company reported Q2 2026 EPS of $0.46, missing expectations, while revenue declined 19.6% year-over-year. Recent product expansions in battery systems and U.S. manufacturing commitments provide growth catalysts, though residential solar demand remains volatile. Valuation metrics show a P/E of 41.46 and P/S of 4.2, reflecting premium pricing amid earnings normalization.

Outlook remains cautiously optimistic with analyst consensus price target of $45.37 offering 8% upside potential. Key opportunities include European storage growth and AI data center initiatives, while risks center on U.S. demand weakness and competitive pressures. The stock faces near-term resistance at $43-$45 levels with institutional ownership showing mixed positioning through recent filings.

Pfizer Inc

Pfizer (PFE) trades at $26.62, down 0.45% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.86. The company reported three consecutive quarterly earnings beats in 2026, with Q3 2026 EPS expected at $0.79. Revenue for 2025 was $62.58 billion, with a net income margin of 12.41%, though 2026 projections show a decline to 6.8%. Positive news highlights pipeline advancements in obesity and oncology therapies.

Pfizer presents a mixed outlook: bullish technicals and analyst support contrast with declining profit margins and patent cliff risks. Investment opportunities include a solid dividend yield and catalyst-rich pipeline in 2026, but risks involve revenue volatility post-COVID and competitive pressures. The stock's current valuation at a P/E of 35.59 may limit near-term upside absent earnings acceleration.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Enphase Energy Inc

Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.

Read more on ENPH

About Pfizer Inc

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Read more on PFE